|
pubmed:abstractText |
The role of PPARgamma in adipocyte differentiation has fueled intense interest in the function of this steroid nuclear receptor for regulation of malignant cell growth and differentiation. Given the antiproliferative and differentiating effects of PPARgamma ligands on liposarcoma cells, investigation of PPARgamma expression and ligand activation in other solid tumors such as breast, colon, and prostate cancers ensued. The anticancer effects of PPARgamma ligands in cell culture and rodent models of a multitude of tumor types suggest broad applicability of these agents to cancer therapy. This review focuses on the clinical use of PPARgamma ligands, specifically the thiazolidinediones, for the treatment and prevention of cancer.
|
